Gross margin of 31.7% is the weakest print in the series and 450 basis points below the 36.2% recorded in 2024Q1, so pricing or mix pressure is real but secondary to the overhead problem: the operating margin fell from 14.3% to 0.3% while net margin slipped to -2.2%. Because this occurred in a quarter where revenue grew 14.2% year over year, the read-through is that the current cost structure no longer carries meaningful operating leverage, and investors should treat gross profit dollars, not net margin, as the more reliable indicator of underlying earning power while losses persist. Quarterly volatility in stock-based compensation, noted in prior filings review, further complicates any attempt to normalize the net figure.

The decay appears driven by both halves of the DuPont identity: net margin compression and an asset turnover ratio that has slipped from 0.33 to 0.30, meaning each dollar of assets supports less profitable revenue than two years ago. That ROE is negative despite a debt-to-equity ratio of only 0.17 indicates the shortfall is an earnings problem rather than a leverage problem, so the return shortfall would not be repaired by further balance sheet optimization. If returns stay pinned near zero while goodwill has grown to $11.0M, investors should monitor whether the acquired intangibles remain supportable on this earnings base.

Days payable outstanding at 99 now exceed days sales outstanding at 95, a configuration that flatters the cycle math but may indicate the company is leaning on vendor terms to fund a receivables book that still runs roughly three months. This sits in tension with the cash flow statement, where working capital swung to a $6.0M use in the same quarter, suggesting the earlier cycle lengthening may have been inventory and receivables liquidation rather than durable process gains. The combination of a shorter cycle with declining asset turnover (0.30 versus 0.33) reads more like balance sheet shrinkage than efficiency improvement, and warrants investigation alongside DSO trends in coming quarters.

Absolute debt has been reduced roughly 40% since 2024Q1 to about $28.8M, which compares favorably with Aviat's 0.35 debt-to-equity though it remains above Gilat's 0.02, so refinancing risk on the outstanding principal appears contained in isolation. The concern is the denominator: coverage has fallen from 7.98x in 2024Q3 to under 1x, and the debt-to-EBITDA series is violently unstable (3.22x to 18.19x), which implies EBITDA has become too small and too volatile to absorb even modest interest expense reliably. On reported figures, debt service comfort now depends more on an operating margin recovery than on further paydown, and the trend suggests margin, not balance sheet, is the binding constraint.

The trailing P/E of -94.0x carries no analytical content given the loss, so the valuation case rests on forward EV/EBITDA of 5.88x versus a trailing 8.29x — a discount that presupposes EBITDA expansion from a base where quarterly operating margin is 0.3%. Price-to-FCF of 14.09x looks reasonable against a 1.9% FCF margin, but the cash flow history shows that figure swinging from -3.0% to 10.5% within five quarters, so the multiple is highly sensitive to working capital timing rather than to steady-state earnings. The 1.14x price-to-book sits above both Aviat (1.00x) and Gilat (0.95x), which may indicate the market is paying for recovery optionality rather than for demonstrated returns on the existing capital base.